IL2 and non-Hodgkin lymphoma: In a study by Wilhelm et al., 19 patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) or MM received ZOL and IL-2 infusions to stimulate γδ T cell expansion in vivo.